Alder BioPharmaceuticals, Inc. Securities Litigation
On or around 01/10/2020 (Notice of voluntarily dismissal)
Filing Date: September 30, 2019
According to the Complaint, Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on transforming migraine treatment through the discovery, development, and commercialization of novel therapeutic antibodies.
This action stems from a proposed transaction announced on September 16, 2019, pursuant to which Alder BioPharmaceuticals, Inc. will be acquired by H. Lundbeck A/S.
On September 16, 2019, Alder’s Board of Directors caused the Company to enter into an agreement and plan of merger with Lundbeck.
On September 23, 2019, Defendants filed a Solicitation/Recommendation Statement with the United States Securities and Exchange Commission in connection with the Proposed Transaction. The Complaint alleges that the Solicitation Statement omits material information with respect to the Proposed Transaction, which renders the Solicitation Statement false and misleading.
This case was voluntarily dismissed on January 10, 2020.
Company & Securities Information
Defendant: Alder BioPharmaceuticals, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ALDR
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Jack Wolf, et al. v. Alder BioPharmaceuticals, Inc., et al.
COURT: D. Delaware
DOCKET #: 19-CV-01838
JUDGE: Hon. Maryellen Noreika
DATE FILED: 09/30/2019
CLASS PERIOD START: 09/16/2019
CLASS PERIOD END: 09/30/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Rigrodsky & Long, P.A. (Wilmington)
RM Law, P.C. (Berwyn)
First Identified Complaint (FIC) Filings:
Complaint for Violation of the Securities Exchange Act of 1934
U.S. District Court Civil Docket
Plaintiff's Notice of Voluntary Dismissal
—Reference Complaint Complaint Related Data is not available
Related District Court Filings
—Related District Court Filings Data is not available